Aptevo Therapeutics Inc. reported its financial results for the quarter ended March 31, 2025, and provided an update on the ongoing mipletamig clinical trial. The company highlighted that 9 out of 10 frontline AML patients achieved remission with mipletamig in combination with standard of care across two trials.
The mipletamig triplet combination continues to outperform the standard doublet benchmark, underscoring the strength of Aptevo's therapeutic approach. This consistent efficacy data reinforces mipletamig's potential to redefine frontline AML treatment, particularly for patients unfit for intensive chemotherapy.
A critical safety aspect noted was the absence of cytokine release syndrome (CRS) observed in the ongoing RAINIER trial, supporting mipletamig's favorable safety profile for frontline AML. Cohort 2 enrollment is now complete, and Cohort 3 is actively enrolling, indicating steady progress in the clinical development program.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.